Jennifer Morganroth, MD, MBA

Dr. Jennifer Morganroth is a neurologist and clinical investigator specializing in neuromuscular medicine with a distinct focus on the intersection of clinical excellence and healthcare innovation. Her work is particularly centered on advancing the care delivery infrastructure for Amyotrophic Lateral Sclerosis (ALS) and expanding access to emerging genetic therapies. Dr. Morganroth is actively shaping how health systems prepare for and deliver novel ALS therapies, with an emphasis on aligning clinical care, research operations, and translational innovation.

Education

• Dr. Morganroth completed her neurology residency at the Perelman School of Medicine at the University of Pennsylvania, where she also earned her MD and MBA, and a fellowship in Neuromuscular/EMG at Columbia University. Currently an Instructor at Harvard Medical School and a clinical investigator at Massachusetts General Hospital, her research and publications focus on ALS and precision genetic medicine.

Professional Accomplishments

• Genetic Therapy Delivery & Clinical Infrastructure: She developed a foundational model for the clinical delivery of intrathecal and genetic therapies (the "Qalsody/Tofersen model") specifically for patients with SOD1-ALS. She also developed a national model estimating the number of symptomatic and asymptomatic ALS gene variant carriers requiring longitudinal surveillance and care, informing ALS clinic infrastructure planning as genetic testing expands.
• Clinical Trial Access & Enrollment Innovation: She focuses on improving trial access through patient identification, eligibility assessment, and workflow integration, including data-driven and AI-enabled approaches to identify eligible patients earlier and reduce operational barriers to enrollment.
• Proactive & At-Risk Care Models: She established one of the first clinics in the country for asymptomatic individuals carrying ALS-causative gene variants (“MGH Proactive Care Clinic”), providing longitudinal monitoring and enabling earlier intervention as preventive trials emerge. Her work also includes identifying and validating novel biomarkers to support earlier detection and trial readiness.
• Translational Innovation & Strategy: With an MBA from Wharton in Health Care Management, she advises at the intersection of clinical care, research operations, and commercialization, with experience across Penn Health Tech, Columbia BioMedX, and 4Catalyzer. She is engaged with the Mass General Brigham innovation ecosystem and was selected for the Commercialization & Innovation Leadership Program (CILP).

At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.